Increasing cervical penetrability in sheep by long-acting treatments with oxytocin (Carbetocin) and/or prostaglandin E2 (Dinoprostone).

Rodríguez-Piñón M, Casuriaga D, García-Barcelo G, Fila D, Gil J

Domestic animal endocrinology8 Feb 2025Cited by 1 (Europe PMC)

PMID39933278DOI10.1016/j.domaniend.2025.106920PepBankPUB-39933278

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

3 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In synchronized ewes, cervical penetrability remained unchanged from 42 to 68 h post eCG with carbetocin, whereas it decreased in control ewes.
In plain wordsIn ewes, carbetocin kept the cervix open to the probe, while it narrowed in untreated ewes.
Peptide
Oxytocin
Outcome
No significant changeCervical penetrability from 42 to 68 h post eCG, carbetocin alone
Study
sheepn: not reported in source
synchronized ewes (12 days MAP-eCG)
Comparator
Control (saline and placebo intravaginal device)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
40 μg · intramuscularAs given in this study (sheep).
Source sentences
Summary
Cervical penetrability increased from 0 h to 42 h post eCG (P < 0.003) in all groups, then decrease in Group C (P < 0.03) from 42 to 68 h post eCG, whereas remained unchanged in Groups Cb and Cb+Dp or increase at 54 h post eCG in Group Dp (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to study the effect of long-acting treatments with oxytocin (Carbetocin, Cb) and/or prostaglandin E2 (Dinoprostone, Dp) on cervical penetrability and collagenolysis in synchronized ewes (12 days MAP-eCG).
Summary · context
At 42 h post eCG, ewes were treated with Cb (Group Cb, n = 6, 40 μg, i.m., Decomotón, Laboratorios Callier, Uruguay); Dp (Group Dp, n = 10, 10 mg, slow-release intravaginal device, Propess®, Ferring Pharmaceuticals Ltd., West Drayton, UK); combined Cb and Dp treatment (Group Cb+Dp, n = 8) and saline…
Report a problemFND-3993327801
02AnimalAnimal study (in vivo)Efficacy outcome
In synchronized ewes, cervical collagen concentration at 54 h post eCG was lower with carbetocin than in the other groups.
In plain wordsIn ewes, the cervix held less collagen after carbetocin than in the other groups.
Peptide
Oxytocin
Outcome
DecreaseCervical collagen concentration at 54 h post eCG, carbetocin alone
Study
sheepn: not reported in source
synchronized ewes (12 days MAP-eCG)
Comparator
Control, dinoprostone and carbetocin plus dinoprostone groups
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
40 μg · intramuscularAs given in this study (sheep).
Source sentences
Summary
At 54 h post eCG, collagen concentration was lower in Group Cb than in the others groups (P < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to study the effect of long-acting treatments with oxytocin (Carbetocin, Cb) and/or prostaglandin E2 (Dinoprostone, Dp) on cervical penetrability and collagenolysis in synchronized ewes (12 days MAP-eCG).
Summary · context
At 42 h post eCG, ewes were treated with Cb (Group Cb, n = 6, 40 μg, i.m., Decomotón, Laboratorios Callier, Uruguay); Dp (Group Dp, n = 10, 10 mg, slow-release intravaginal device, Propess®, Ferring Pharmaceuticals Ltd., West Drayton, UK); combined Cb and Dp treatment (Group Cb+Dp, n = 8) and saline…
Report a problemFND-3993327804
03AnimalAnimal study (in vivo)Efficacy outcome
In synchronized ewes, the ratio of activated to latent MMP-2 activity in the cervix was greater with carbetocin than in the control group.
In plain wordsIn ewes, carbetocin raised the share of active collagen-degrading enzyme in the cervix compared with untreated ewes.
Peptide
Oxytocin
Outcome
IncreaseMMP-2 activated to latent activity ratio, carbetocin alone
Study
sheepn: not reported in source
synchronized ewes (12 days MAP-eCG)
Comparator
Control (saline and placebo intravaginal device)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
40 μg · intramuscularAs given in this study (sheep).
Source sentences
Summary
the ratio between the activity of the activated and latent forms of MMP-2 was greater in Groups Cb and Cb+Dp than in Group C (P < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to study the effect of long-acting treatments with oxytocin (Carbetocin, Cb) and/or prostaglandin E2 (Dinoprostone, Dp) on cervical penetrability and collagenolysis in synchronized ewes (12 days MAP-eCG).
Summary · context
At 42 h post eCG, ewes were treated with Cb (Group Cb, n = 6, 40 μg, i.m., Decomotón, Laboratorios Callier, Uruguay); Dp (Group Dp, n = 10, 10 mg, slow-release intravaginal device, Propess®, Ferring Pharmaceuticals Ltd., West Drayton, UK); combined Cb and Dp treatment (Group Cb+Dp, n = 8) and saline…
Report a problemFND-3993327805

Studies that did not test the peptide alone4

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

04AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome
In synchronized ewes, cervical penetrability remained unchanged from 42 to 68 h post eCG with combined carbetocin and dinoprostone, whereas it decreased in control ewes.
In plain wordsIn ewes, a carbetocin and dinoprostone combination kept the cervix open, while it narrowed in untreated ewes.
Peptide
Oxytocin
Outcome
No significant changeCervical penetrability from 42 to 68 h post eCG, carbetocin plus dinoprostone
Study
sheepn: not reported in source
synchronized ewes (12 days MAP-eCG)
Comparator
Control (saline and placebo intravaginal device)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Cervical penetrability increased from 0 h to 42 h post eCG (P < 0.003) in all groups, then decrease in Group C (P < 0.03) from 42 to 68 h post eCG, whereas remained unchanged in Groups Cb and Cb+Dp or increase at 54 h post eCG in Group Dp (P < 0.05).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to study the effect of long-acting treatments with oxytocin (Carbetocin, Cb) and/or prostaglandin E2 (Dinoprostone, Dp) on cervical penetrability and collagenolysis in synchronized ewes (12 days MAP-eCG).
Summary · context
At 42 h post eCG, ewes were treated with Cb (Group Cb, n = 6, 40 μg, i.m., Decomotón, Laboratorios Callier, Uruguay); Dp (Group Dp, n = 10, 10 mg, slow-release intravaginal device, Propess®, Ferring Pharmaceuticals Ltd., West Drayton, UK); combined Cb and Dp treatment (Group Cb+Dp, n = 8) and saline…
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3993327802
05AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome
In synchronized ewes, cervical penetrability at 54 h post eCG was higher in the treated groups (carbetocin, dinoprostone, and both) than in the control group.
In plain wordsIn ewes, the cervix was more open in all treated groups together than in untreated ewes. This result does not isolate carbetocin.
Peptide
Oxytocin
Outcome
IncreaseCervical penetrability at 54 h post eCG, all treated groups pooled
Study
sheepn: not reported in source
synchronized ewes (12 days MAP-eCG)
Comparator
Control (saline and placebo intravaginal device)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Thus, there was higher cervical penetrability in treated groups than Group C at the expected time of artificial insemination (54 h post eCG).
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to study the effect of long-acting treatments with oxytocin (Carbetocin, Cb) and/or prostaglandin E2 (Dinoprostone, Dp) on cervical penetrability and collagenolysis in synchronized ewes (12 days MAP-eCG).
Summary · context
At 42 h post eCG, ewes were treated with Cb (Group Cb, n = 6, 40 μg, i.m., Decomotón, Laboratorios Callier, Uruguay); Dp (Group Dp, n = 10, 10 mg, slow-release intravaginal device, Propess®, Ferring Pharmaceuticals Ltd., West Drayton, UK); combined Cb and Dp treatment (Group Cb+Dp, n = 8) and saline…
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3993327803
06AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome
In synchronized ewes, the ratio of activated to latent MMP-2 activity in the cervix was greater with combined carbetocin and dinoprostone than in the control group.
In plain wordsIn ewes, a carbetocin and dinoprostone combination raised the share of active collagen-degrading enzyme compared with untreated ewes.
Peptide
Oxytocin
Outcome
IncreaseMMP-2 activated to latent activity ratio, carbetocin plus dinoprostone
Study
sheepn: not reported in source
synchronized ewes (12 days MAP-eCG)
Comparator
Control (saline and placebo intravaginal device)
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
the ratio between the activity of the activated and latent forms of MMP-2 was greater in Groups Cb and Cb+Dp than in Group C (P < 0.05)
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to study the effect of long-acting treatments with oxytocin (Carbetocin, Cb) and/or prostaglandin E2 (Dinoprostone, Dp) on cervical penetrability and collagenolysis in synchronized ewes (12 days MAP-eCG).
Summary · context
At 42 h post eCG, ewes were treated with Cb (Group Cb, n = 6, 40 μg, i.m., Decomotón, Laboratorios Callier, Uruguay); Dp (Group Dp, n = 10, 10 mg, slow-release intravaginal device, Propess®, Ferring Pharmaceuticals Ltd., West Drayton, UK); combined Cb and Dp treatment (Group Cb+Dp, n = 8) and saline…
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3993327806
07AnimalNot a test of Oxytocin aloneAnimal study (in vivo)Efficacy outcome
In synchronized ewes, combined carbetocin and dinoprostone did not enhance the effects induced by each hormone given separately.
In plain wordsIn ewes, giving carbetocin and dinoprostone together did not work better than giving either one alone.
Peptide
Oxytocin
Outcome
No significant changeCervical effect of combined carbetocin and dinoprostone versus each alone
Study
sheepn: not reported in source
synchronized ewes (12 days MAP-eCG)
Comparator
Carbetocin alone and dinoprostone alone
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Source sentences
Summary
Furthermore, combined treatment with Cb and Dp did not enhance the effects induced by each hormone administered separately.
2 context sentences(design, population, supporting numbers)
Summary · context
The aim was to study the effect of long-acting treatments with oxytocin (Carbetocin, Cb) and/or prostaglandin E2 (Dinoprostone, Dp) on cervical penetrability and collagenolysis in synchronized ewes (12 days MAP-eCG).
Summary · context
At 42 h post eCG, ewes were treated with Cb (Group Cb, n = 6, 40 μg, i.m., Decomotón, Laboratorios Callier, Uruguay); Dp (Group Dp, n = 10, 10 mg, slow-release intravaginal device, Propess®, Ferring Pharmaceuticals Ltd., West Drayton, UK); combined Cb and Dp treatment (Group Cb+Dp, n = 8) and saline…
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3993327807

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 00:50 UTC
Study results updated
Version 1
9 Oct 2026, 02:48 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

Keywords

PepBank is a research reference. Talk to a doctor before you use any peptide.